deltatrials
Unknown NA INTERVENTIONAL 2-arm NCT03380650

Study of DA+LDD in the Treatment of Femoropopliteal Occlusive Disease

Study of Combined Use of Directional Atherectomy and Local Drug Delivery With Balloon Catheter System in the Treatment of Femoropopliteal Occlusive Disease

Sponsor: RenJi Hospital

Updated 6 times since 2018 Last updated: Dec 20, 2017 Started: Jan 1, 2018 Primary completion: Dec 30, 2018 Completion: Dec 30, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Endovascular Treatment and Peripheral Artery Disease, this trial is ongoing. The trial is conducted by RenJi Hospital and has accumulated 6 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshotNot Yet Recruiting~Jun 2018 – ~Feb 2020 · 20 months · monthly snapshotNot Yet Recruiting~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

6 versions recorded
  1. Sep 2024 — Present [monthly]

    Unknown NA

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown NA

    Status: Unknown StatusUnknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status NA

  4. Feb 2020 — Jan 2021 [monthly]

    Unknown Status NA

    Status: Not Yet RecruitingUnknown Status

  5. Jun 2018 — Feb 2020 [monthly]

    Not Yet Recruiting NA

Show 1 earlier version
  1. Jan 2018 — Jun 2018 [monthly]

    Not Yet Recruiting NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • RenJi Hospital
Data source: RenJi Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.